GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Home・Akcijų sąrašas・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Uždarymo kaina

288.45 1.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

286.85

Max

289.85

Pagrindiniai rodikliai
By Trading Economics
Pajamos	22B 49B
Pardavimai	18B 97B
P/E Sektoriaus vid.	10.403 49.701
Pelnas, tenkantis vienai akcijai	10.91
Dividendų pajamingumas	4.09
Pelno marža	50.15
Darbuotojai	67,900
EBITDA	32B 69B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+9.53% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	4.09% 2.39%
Kitas uždarbis	2026-08-05
Kita Ex Dividend data	2026-08-13

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	8.6B 1.3T
Ankstesnė atidarymo kaina	287.19
Ankstesnė uždarymo kaina	288.45

Novo Nordisk A-S (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

2026-05-06 07:30; UTC

Uždarbis

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

2026-05-06 06:19; UTC

Uždarbis

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

2026-05-18 13:10; UTC

Rinkos pokalbiai

Uždarbis

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

2026-05-12 12:05; UTC

Karštos akcijos

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

2026-05-12 10:51; UTC

Karštos akcijos

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

2026-05-12 09:42; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-12 09:08; UTC

Karštos akcijos

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-07 09:30; UTC

Uždarbis

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

2026-05-06 12:36; UTC

Uždarbis

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

2026-05-06 10:53; UTC

Karštos akcijos

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

2026-05-06 10:12; UTC

Uždarbis

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

2026-05-06 09:58; UTC

Uždarbis

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

2026-05-06 09:35; UTC

Karštos akcijos

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

2026-05-06 08:13; UTC

Rinkos pokalbiai

Uždarbis

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

2026-05-06 07:43; UTC

Rinkos pokalbiai

Uždarbis

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

2026-05-06 07:00; UTC

Uždarbis

Novo Nordisk Shares Rise 5.5% After 1Q Results

2026-05-06 06:34; UTC

Uždarbis

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

2026-05-06 06:26; UTC

Uždarbis

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

2026-05-06 06:26; UTC

Uždarbis

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

2026-05-06 06:24; UTC

Uždarbis

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

2026-05-06 06:20; UTC

Uždarbis

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

2026-05-06 06:19; UTC

Uždarbis

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

2026-05-06 06:13; UTC

Uždarbis

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

2026-05-06 06:13; UTC

Uždarbis

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

2026-05-06 06:12; UTC

Uždarbis

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

2026-05-06 05:43; UTC

Uždarbis

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

2026-05-06 05:42; UTC

Uždarbis

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

2026-05-06 05:40; UTC

Uždarbis

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Akcijų palyginimas

Kainos pokytis

Novo Nordisk A-S (Class B) Prognozė

Kainos tikslas

By TipRanks

9.53% į viršų

12 mėnesių prognozė

Vidutinis 1,162.73 DKK 9.53%

Aukščiausias 1,550 DKK

Žemiausias 720 DKK

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S (Class B) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Novo Nordisk A-S (Class B) akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.